Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...
Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...
As East Asia prepares to shut down for the Lunar New Year holiday and looks towards the Year of the Snake, it’s time to look back at bitcoin BTC $66,797.21 and the CoinDesk 20 (CD20)’s performance ...
Originally developed as a more-potent follow-up to Roche's long-established CD20-directed antibody Rituxan (rituximab) for ...
Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have been ...
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "CD19/CD20 Bi-Specific CAR-T - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. CD19/CD20 Bi-Specific CAR-T ...
From 20 months to upto 5 years, blocking CD20 significantly improved OS in CLL patients. Patients with relapsed/refractory chronic lymphocytic leukemia (CLL) lived twice as long when treated with ...
AbbVie has fired back in the fierce fight for the CD20 bispecific market. Phase 1/2 data show AbbVie and Genmab’s epcoritamab triggers responses in heavily pretreated blood cancer patients, although ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results